Copyright Reports & Markets. All rights reserved.

Global Phelan-McDermid Syndrome (PMS) Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Phelan-McDermid Syndrome (PMS) by Type
    • 1.3.1 Overview: Global Phelan-McDermid Syndrome (PMS) Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Phelan-McDermid Syndrome (PMS) Consumption Value Market Share by Type in 2025
    • 1.3.3 Applied Behavior Analysis
    • 1.3.4 Occupational Therapy
    • 1.3.5 Physical Therapy
    • 1.3.6 Others
  • 1.4 Global Phelan-McDermid Syndrome (PMS) Market by Application
    • 1.4.1 Overview: Global Phelan-McDermid Syndrome (PMS) Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospitals
    • 1.4.3 Specialty Clinics
    • 1.4.4 Others
  • 1.5 Global Phelan-McDermid Syndrome (PMS) Market Size & Forecast
  • 1.6 Global Phelan-McDermid Syndrome (PMS) Market Size and Forecast by Region
    • 1.6.1 Global Phelan-McDermid Syndrome (PMS) Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global Phelan-McDermid Syndrome (PMS) Market Size by Region, (2021-2032)
    • 1.6.3 North America Phelan-McDermid Syndrome (PMS) Market Size and Prospect (2021-2032)
    • 1.6.4 Europe Phelan-McDermid Syndrome (PMS) Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific Phelan-McDermid Syndrome (PMS) Market Size and Prospect (2021-2032)
    • 1.6.6 South America Phelan-McDermid Syndrome (PMS) Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa Phelan-McDermid Syndrome (PMS) Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Cellcentric
    • 2.1.1 Cellcentric Details
    • 2.1.2 Cellcentric Major Business
    • 2.1.3 Cellcentric Phelan-McDermid Syndrome (PMS) Product and Solutions
    • 2.1.4 Cellcentric Phelan-McDermid Syndrome (PMS) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Cellcentric Recent Developments and Future Plans
  • 2.2 Celgen
    • 2.2.1 Celgen Details
    • 2.2.2 Celgen Major Business
    • 2.2.3 Celgen Phelan-McDermid Syndrome (PMS) Product and Solutions
    • 2.2.4 Celgen Phelan-McDermid Syndrome (PMS) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Celgen Recent Developments and Future Plans
  • 2.3 EpiGentek
    • 2.3.1 EpiGentek Details
    • 2.3.2 EpiGentek Major Business
    • 2.3.3 EpiGentek Phelan-McDermid Syndrome (PMS) Product and Solutions
    • 2.3.4 EpiGentek Phelan-McDermid Syndrome (PMS) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 EpiGentek Recent Developments and Future Plans
  • 2.4 Oryzon Genomics SA
    • 2.4.1 Oryzon Genomics SA Details
    • 2.4.2 Oryzon Genomics SA Major Business
    • 2.4.3 Oryzon Genomics SA Phelan-McDermid Syndrome (PMS) Product and Solutions
    • 2.4.4 Oryzon Genomics SA Phelan-McDermid Syndrome (PMS) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Oryzon Genomics SA Recent Developments and Future Plans
  • 2.5 Astex Pharmaceutucals
    • 2.5.1 Astex Pharmaceutucals Details
    • 2.5.2 Astex Pharmaceutucals Major Business
    • 2.5.3 Astex Pharmaceutucals Phelan-McDermid Syndrome (PMS) Product and Solutions
    • 2.5.4 Astex Pharmaceutucals Phelan-McDermid Syndrome (PMS) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Astex Pharmaceutucals Recent Developments and Future Plans
  • 2.6 Sonic Genetics
    • 2.6.1 Sonic Genetics Details
    • 2.6.2 Sonic Genetics Major Business
    • 2.6.3 Sonic Genetics Phelan-McDermid Syndrome (PMS) Product and Solutions
    • 2.6.4 Sonic Genetics Phelan-McDermid Syndrome (PMS) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Sonic Genetics Recent Developments and Future Plans
  • 2.7 Mendelian
    • 2.7.1 Mendelian Details
    • 2.7.2 Mendelian Major Business
    • 2.7.3 Mendelian Phelan-McDermid Syndrome (PMS) Product and Solutions
    • 2.7.4 Mendelian Phelan-McDermid Syndrome (PMS) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Mendelian Recent Developments and Future Plans
  • 2.8 AMO Pharma
    • 2.8.1 AMO Pharma Details
    • 2.8.2 AMO Pharma Major Business
    • 2.8.3 AMO Pharma Phelan-McDermid Syndrome (PMS) Product and Solutions
    • 2.8.4 AMO Pharma Phelan-McDermid Syndrome (PMS) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 AMO Pharma Recent Developments and Future Plans
  • 2.9 Neuren Pharmaceuticals Limited
    • 2.9.1 Neuren Pharmaceuticals Limited Details
    • 2.9.2 Neuren Pharmaceuticals Limited Major Business
    • 2.9.3 Neuren Pharmaceuticals Limited Phelan-McDermid Syndrome (PMS) Product and Solutions
    • 2.9.4 Neuren Pharmaceuticals Limited Phelan-McDermid Syndrome (PMS) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Neuren Pharmaceuticals Limited Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Phelan-McDermid Syndrome (PMS) Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Phelan-McDermid Syndrome (PMS) by Company Revenue
    • 3.2.2 Top 3 Phelan-McDermid Syndrome (PMS) Players Market Share in 2025
    • 3.2.3 Top 6 Phelan-McDermid Syndrome (PMS) Players Market Share in 2025
  • 3.3 Phelan-McDermid Syndrome (PMS) Market: Overall Company Footprint Analysis
    • 3.3.1 Phelan-McDermid Syndrome (PMS) Market: Region Footprint
    • 3.3.2 Phelan-McDermid Syndrome (PMS) Market: Company Product Type Footprint
    • 3.3.3 Phelan-McDermid Syndrome (PMS) Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Phelan-McDermid Syndrome (PMS) Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Phelan-McDermid Syndrome (PMS) Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Phelan-McDermid Syndrome (PMS) Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Phelan-McDermid Syndrome (PMS) Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Phelan-McDermid Syndrome (PMS) Consumption Value by Type (2021-2032)
  • 6.2 North America Phelan-McDermid Syndrome (PMS) Market Size by Application (2021-2032)
  • 6.3 North America Phelan-McDermid Syndrome (PMS) Market Size by Country
    • 6.3.1 North America Phelan-McDermid Syndrome (PMS) Consumption Value by Country (2021-2032)
    • 6.3.2 United States Phelan-McDermid Syndrome (PMS) Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Phelan-McDermid Syndrome (PMS) Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Phelan-McDermid Syndrome (PMS) Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Phelan-McDermid Syndrome (PMS) Consumption Value by Type (2021-2032)
  • 7.2 Europe Phelan-McDermid Syndrome (PMS) Consumption Value by Application (2021-2032)
  • 7.3 Europe Phelan-McDermid Syndrome (PMS) Market Size by Country
    • 7.3.1 Europe Phelan-McDermid Syndrome (PMS) Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Phelan-McDermid Syndrome (PMS) Market Size and Forecast (2021-2032)
    • 7.3.3 France Phelan-McDermid Syndrome (PMS) Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Phelan-McDermid Syndrome (PMS) Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Phelan-McDermid Syndrome (PMS) Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Phelan-McDermid Syndrome (PMS) Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Phelan-McDermid Syndrome (PMS) Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Phelan-McDermid Syndrome (PMS) Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Phelan-McDermid Syndrome (PMS) Market Size by Region
    • 8.3.1 Asia-Pacific Phelan-McDermid Syndrome (PMS) Consumption Value by Region (2021-2032)
    • 8.3.2 China Phelan-McDermid Syndrome (PMS) Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Phelan-McDermid Syndrome (PMS) Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Phelan-McDermid Syndrome (PMS) Market Size and Forecast (2021-2032)
    • 8.3.5 India Phelan-McDermid Syndrome (PMS) Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Phelan-McDermid Syndrome (PMS) Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Phelan-McDermid Syndrome (PMS) Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Phelan-McDermid Syndrome (PMS) Consumption Value by Type (2021-2032)
  • 9.2 South America Phelan-McDermid Syndrome (PMS) Consumption Value by Application (2021-2032)
  • 9.3 South America Phelan-McDermid Syndrome (PMS) Market Size by Country
    • 9.3.1 South America Phelan-McDermid Syndrome (PMS) Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Phelan-McDermid Syndrome (PMS) Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Phelan-McDermid Syndrome (PMS) Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Phelan-McDermid Syndrome (PMS) Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Phelan-McDermid Syndrome (PMS) Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Phelan-McDermid Syndrome (PMS) Market Size by Country
    • 10.3.1 Middle East & Africa Phelan-McDermid Syndrome (PMS) Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Phelan-McDermid Syndrome (PMS) Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Phelan-McDermid Syndrome (PMS) Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Phelan-McDermid Syndrome (PMS) Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Phelan-McDermid Syndrome (PMS) Market Drivers
  • 11.2 Phelan-McDermid Syndrome (PMS) Market Restraints
  • 11.3 Phelan-McDermid Syndrome (PMS) Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Phelan-McDermid Syndrome (PMS) Industry Chain
  • 12.2 Phelan-McDermid Syndrome (PMS) Upstream Analysis
  • 12.3 Phelan-McDermid Syndrome (PMS) Midstream Analysis
  • 12.4 Phelan-McDermid Syndrome (PMS) Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Phelan-McDermid Syndrome (PMS) market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    Phelan-McDermid syndrome (PMS) is a rare genetic condition that causes developmental and speech delays, behavioral problems and a weakened or no ability to feel pain or sweat. Phelan-McDermid syndrome is a congenital condition (condition that is present at birth) that can affect people of all genders.
    Phelan-McDermid Syndrome (PMS) is a rare genetic disorder caused by the deletion or mutation of the terminal end of chromosome 22. It is characterized by developmental delays, intellectual disabilities, and various physical and neurological abnormalities.
    Market Overview: The market for Phelan-McDermid Syndrome is relatively small due to the rarity of the condition. It primarily focuses on providing diagnostic tests, therapeutic interventions, and supportive care for patients with PMS.
    Diagnostic Tests: The market includes companies that offer genetic testing and diagnostic services to identify chromosomal abnormalities associated with Phelan-McDermid Syndrome. These tests help in confirming the diagnosis of PMS and identifying specific genetic variations.
    Therapeutic Interventions: Currently, there is no specific cure for Phelan-McDermid Syndrome. However, research and clinical trials are ongoing to develop targeted therapies that can alleviate the symptoms and improve the quality of life for individuals with PMS. The market may involve pharmaceutical companies working on potential treatments or therapies targeting specific pathways affected by PMS.
    Supportive Care: The market may also include companies providing supportive care products and services for individuals with Phelan-McDermid Syndrome. This may include therapeutic interventions, assistive devices, and rehabilitation services aimed at managing symptoms, promoting development, and improving the overall well-being of patients with PMS.
    This report is a detailed and comprehensive analysis for global Phelan-McDermid Syndrome (PMS) market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Phelan-McDermid Syndrome (PMS) market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Phelan-McDermid Syndrome (PMS) market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Phelan-McDermid Syndrome (PMS) market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Phelan-McDermid Syndrome (PMS) market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Phelan-McDermid Syndrome (PMS)
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Phelan-McDermid Syndrome (PMS) market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Cellcentric, Celgen, EpiGentek, Oryzon Genomics SA, Astex Pharmaceutucals, Sonic Genetics, Mendelian, AMO Pharma, Neuren Pharmaceuticals Limited, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Phelan-McDermid Syndrome (PMS) market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Applied Behavior Analysis
    Occupational Therapy
    Physical Therapy
    Others
    Market segment by Application
    Hospitals
    Specialty Clinics
    Others
    Market segment by players, this report covers
    Cellcentric
    Celgen
    EpiGentek
    Oryzon Genomics SA
    Astex Pharmaceutucals
    Sonic Genetics
    Mendelian
    AMO Pharma
    Neuren Pharmaceuticals Limited
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Phelan-McDermid Syndrome (PMS) product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Phelan-McDermid Syndrome (PMS), with revenue, gross margin, and global market share of Phelan-McDermid Syndrome (PMS) from 2021 to 2026.
    Chapter 3, the Phelan-McDermid Syndrome (PMS) competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Phelan-McDermid Syndrome (PMS) market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Phelan-McDermid Syndrome (PMS).
    Chapter 13, to describe Phelan-McDermid Syndrome (PMS) research findings and conclusion.

    Buy now